Table 1. Clinical characteristics of cases in the two cohorts.
| Histological diagnosis | Cohort 1 | Cohort 2 | ||
|---|---|---|---|---|
| N | % | N | % | |
| Atypical teratoid-rhabdoid tumor | 1 | 3.7 | 4 | 6.7 |
| Grade III ependymoma | 4 | 14.8 | 1 | 1.7 |
| Grade II ependymoma | 1 | 3.7 | 5 | 8.3 |
| Malignant glioma (anaplastic astrocytoma, glioblastoma, high-grade glioma NAS) | 1 | 3.7 | 13 | 21.7 |
| Anaplastic medulloblastoma | 5 | 18.5 | 3 | 5.0 |
| Classic/desmoplastic medulloblastoma | 13 | 48.2 | 20 | 33.3 |
| PNET | 2 | 7.4 | 8 | 13.3 |
| Anaplastic glioneuronal tumor | 1 | 1.7 | ||
| Germ-cell tumor | 4 | 6.7 | ||
| Choroid plexus carcinoma | 1 | 1.7 | ||
| Timing of CSF sampling | N | % | N | % |
| At diagnosis | 21 | 77.8 | 45 | 75.0 |
| During treatment | 3 | 11.1 | 2 | 3.3 |
| During follow-up | 1 | 3.7 | 3 | 5.0 |
| At progression/relapse | 2 | 7.4 | 10 | 16.7 |
| CSF cytology | N | % | N | % |
| Positive | 3 | 11.1 | 5 | 8.3 |
| Negative | 24 | 88.9 | 54 | 90.0 |
| Borderline | 1 | 1.7 | ||
| Metastasis | N | % | N | % |
| No | 17 | 63.0 | 46 | 76.7 |
| Yes | 10 | 37.0 | 14 | 23.3 |
| Total | 27 | 100.0 | 60 | 100.0 |